{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T22:36:19Z","timestamp":1792708579022,"version":"4.5.0"},"reference-count":46,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CIMB"],"abstract":"<jats:p>KMT2A-rearranged (KMT2A-r) acute lymphoblastic leukemia (ALL), particularly in infants, represents one of the most aggressive pediatric hematological malignancies with a historically dismal prognosis. While KMT2A-AFF1 (t(4;11)) is the most prevalent fusion, a diverse array of partner genes exists, each conferring distinct biological and clinical features. This review focuses on the rare but clinically significant KMT2A-AFF3 subtype, which arises from the t(2;11)(q11.2;q23) chromosomal translocation. This review summarizes the molecular pathogenesis driven by the KMT2A-AFF3 fusion oncoprotein, which functions as an aberrant transcriptional complex. This complex hijacks essential epigenetic machinery, including the recruitment of DOT1L and interaction with Menin, leading to pathogenic histone modifications (e.g., H3K79 hypermethylation) and the subsequent upregulation of critical target genes, notably the HOXA cluster and MEIS1, thereby enforcing a B-lymphoid differentiation arrest at the pro-B\/pre-B stage. Clinically, KMT2A-AFF3 ALL is characterized by high-risk features, including infant onset, hyperleukocytosis, central nervous system (CNS) involvement, and a distinct CD10-negative immunophenotype. This review highlights the evidence defining its poor prognosis, which is primarily driven by profound chemoresistance to conventional therapies, including glucocorticoids. Finally, we discuss the rapidly evolving therapeutic landscape, detailing the limitations of standard intensive chemotherapy and the immense promise of novel targeted strategies, such as Menin inhibitors (e.g., Revumenib), DOT1L inhibitors, and immunotherapies (e.g., CAR-T cells, Blinatumomab), which hold the potential to revolutionize outcomes for this high-risk leukemia subtype.<\/jats:p>","DOI":"10.3390\/cimb47120988","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T15:56:41Z","timestamp":1764172601000},"page":"988","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Research Progress on the KMT2A-AFF3 Fusion Gene in Childhood Acute Lymphoblastic Leukemia: Mechanisms, Clinical Implications, and Therapeutic Strategies"],"prefix":"10.3390","volume":"47","author":[{"given":"Yawei","family":"Zhang","sequence":"first","affiliation":[{"name":"Children\u2019s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou 310052, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Liang","sequence":"additional","affiliation":[{"name":"Children\u2019s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou 310052, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): A randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S1470-2045(22)00293-5","article-title":"Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): A randomised, controlled, phase 3 trial","volume":"23","author":"Tam","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa2213093","article-title":"First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia","volume":"388","author":"Eichhorst","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s11864-023-01103-1","article-title":"Measurable Residual Disease in Chronic Lymphocytic Leukemia: Current Understanding and Evolving Role in Clinical Practice","volume":"24","author":"Hilal","year":"2023","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.cancergen.2021.12.005","article-title":"A complex KMT2A::AFF3 fusion resulting from a three-way chromosomal rearrangement in pediatric B lymphoblastic leukemia","volume":"262\u2013263","author":"Miller","year":"2022","journal-title":"Cancer Genet."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1038\/s41375-018-0146-5","article-title":"Obinutuzumab plus bendamustine in previously untreated patients with CLL: A subgroup analysis of the GREEN study","volume":"32","author":"Stilgenbauer","year":"2018","journal-title":"Leukemia"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Ogino, J., and Dou, Y. (2024). Histone methyltransferase KMT2A: Developmental regulation to oncogenic transformation. J. Biol. Chem., 300.","DOI":"10.1016\/j.jbc.2024.107791"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/nrc2253","article-title":"MLL translocations, histone modifications and leukaemia stem-cell development","volume":"7","author":"Krivtsov","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.molcel.2010.01.026","article-title":"AFF4, a component of the ELL\/P-TEFb elongation complex and a shared subunit of MLL chimeras, can link transcription elongation to leukemia","volume":"37","author":"Lin","year":"2010","journal-title":"Mol. Cell"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1101\/gad.2015411","article-title":"The super elongation complex (SEC) and MLL in development and disease","volume":"25","author":"Smith","year":"2011","journal-title":"Genes Dev."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Feng, Y., Wang, Y., Wang, X., He, X., Yang, C., Naseri, A., Pederson, T., Zheng, J., Zhang, S., and Xiao, X. (2020). Simultaneous epigenetic perturbation and genome imaging reveal distinct roles of H3K9me3 in chromatin architecture and transcription. Genome Biol., 21.","DOI":"10.1186\/s13059-020-02201-1"},{"key":"ref_14","first-page":"2823","article-title":"The histone methyltransferase DOT1L: Regulatory functions and a cancer therapy target","volume":"5","author":"Wong","year":"2015","journal-title":"Am. J. Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1182\/bloodadvances.2020001922","article-title":"Specific patterns of H3K79 methylation influence genetic interaction of oncogenes in AML","volume":"4","author":"Kingsley","year":"2020","journal-title":"Blood Adv."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.exphem.2018.10.001","article-title":"Distinct pathways affected by menin versus MLL1\/MLL2 in MLL-rearranged acute myeloid leukemia","volume":"69","author":"Chen","year":"2019","journal-title":"Exp. Hematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1182\/blood.2023022480","article-title":"Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemias","volume":"144","author":"Kwon","year":"2024","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/S2352-3026(20)30433-6","article-title":"Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): A phase 3, multicentre, open-label, randomised trial","volume":"8","author":"Sharman","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1016\/j.celrep.2015.12.003","article-title":"MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199","volume":"13","author":"Benito","year":"2015","journal-title":"Cell Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/S1470-2045(22)00220-0","article-title":"Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141\/VISION): Primary analysis of an open-label, randomised, phase 2 trial","volume":"23","author":"Kater","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"5767","DOI":"10.1038\/s41467-019-13666-5","article-title":"MLL-AF9 initiates transformation from fast-proliferating myeloid progenitors","volume":"10","author":"Chen","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1158\/1538-7445.AM2011-1789","article-title":"Abstract 1789: Auristatin-based antibody-drug conjugates are synergistic in combination with PI3K-AKT-mTOR pathway inhibitors in hematologic malignancies and carcinoma","volume":"71","author":"Lewis","year":"2011","journal-title":"Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1182\/blood.V104.11.525.525","article-title":"MLL Rearranged Infant Acute Lymphoblastic Leukemia Is Characterized by Silencing of the Putative Tumor Suppressor Gene FHIT","volume":"104","author":"Stam","year":"2004","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.1038\/s41467-022-32266-4","article-title":"Multi-omics analysis defines highly refractory RAS burdened immature subgroup of infant acute lymphoblastic leukemia","volume":"13","author":"Isobe","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3919","DOI":"10.1182\/blood.V128.22.3919.3919","article-title":"The Role of STAT5 in HOXA9-Associated Leukemia","volume":"128","author":"Ma","year":"2016","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1182\/blood.2023023154","article-title":"How I treat infant acute lymphoblastic leukemia","volume":"145","author":"Bartram","year":"2025","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/S0140-6736(98)04058-6","article-title":"Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood","volume":"352","author":"Seriu","year":"1998","journal-title":"Lancet"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e70326","DOI":"10.1002\/cam4.70326","article-title":"Recent Developments and Evolving Therapeutic Strategies in KMT2A-Rearranged Acute Leukemia","volume":"13","author":"Yin","year":"2024","journal-title":"Cancer Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1038\/s41379-020-0582-4","article-title":"Pan-sarcoma genomic analysis of KMT2A rearrangements reveals distinct subtypes defined by YAP1-KMT2A-YAP1 and VIM-KMT2A fusions","volume":"33","author":"Massoth","year":"2020","journal-title":"Mod. Pathol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1182\/blood.2019001077","article-title":"Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy","volume":"134","author":"Thompson","year":"2019","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1182\/bloodadvances.2018019398","article-title":"Recurrent CCND3 mutations in MLL-rearranged acute myeloid leukemia","volume":"2","author":"Matsuo","year":"2018","journal-title":"Blood Adv."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s40164-023-00445-8","article-title":"Modelling acquired resistance to DOT1L inhibition exhibits the adaptive potential of KMT2A-rearranged acute lymphoblastic leukemia","volume":"12","author":"Schneider","year":"2023","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Xiao, L., Karsa, M., Ronca, E., Bongers, A., Kosciolek, A., El-Ayoubi, A., Revalde, J.L., Seneviratne, J.A., Cheung, B.B., and Cheung, L.C. (2022). The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia Progression. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.863329"},{"key":"ref_34","first-page":"6020","article-title":"The therapeutic efficacy of pediatric ALL patients with MLL gene rearrangement treated with CCLG-ALL2008 protocol","volume":"22","author":"Sun","year":"2018","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00427-024-00717-1","article-title":"Molecular evolution of transcription factors AF4\/FMR2 family member (AFF) gene family and the role of lamprey AFF3 in cell proliferation","volume":"234","author":"Sun","year":"2024","journal-title":"Dev. Genes Evol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13073-024-01339-y","article-title":"Variant-specific pathophysiological mechanisms of AFF3 differently influence transcriptome profiles","volume":"16","author":"Bassani","year":"2024","journal-title":"Genome Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.clml.2019.03.014","article-title":"Minimal Residual Disease and Survival Outcomes in Patients With Chronic Lymphocytic Leukemia: A Systematic Review and Meta-analysis","volume":"19","author":"Molica","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","article-title":"The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia","volume":"615","author":"Issa","year":"2023","journal-title":"Nature"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1182\/blood-2023-189762","article-title":"Revumenib Monotherapy in Patients with Relapsed\/Refractory KMT2Ar Acute Leukemias: Efficacy and Safety Results from the Augment-101 Phase 1\/2 Study","volume":"142","author":"Aldoss","year":"2023","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2020-134942","article-title":"Preliminary Data on a Phase 1\/2A First in Human Study of the Menin-KMT2A (MLL) Inhibitor KO-539 in Patients with Relapsed or Refractory Acute Myeloid Leukemia","volume":"136","author":"Wang","year":"2020","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1182\/blood-2022-157225","article-title":"Preclinical In Vivo Activity of the Menin Inhibitor Ziftomenib (KO-539) in Pediatric KMT2A-Rearranged Acute Lymphoblastic Leukemia","volume":"140","author":"Falkenstein","year":"2022","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2023-182337","article-title":"Early Results of the Phase I\/II Study Investigating the All-Oral Combination of the Menin Inhibitor Revumenib (SNDX-5613) with Decitabine\/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)","volume":"142","author":"Issa","year":"2023","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.cancergen.2024.06.004","article-title":"Novel gene fusions in human oropharyngeal carcinoma","volume":"286\u2013287","author":"Masago","year":"2024","journal-title":"Cancer Genet."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1080\/10428194.2024.2390572","article-title":"Long-term exposure and response to azacitidine for post-hematopoietic stem cell transplantation relapse of early T-cell precursor acute lymphoblastic leukemia: A case report and review of the literature","volume":"65","author":"Jeanselme","year":"2024","journal-title":"Leuk. Lymphoma"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1089\/dna.2022.0232","article-title":"High Levels of Organochlorines Are Associated with Induction of ABL1 Promoter Methylation in Children with Acute Lymphoblastic Leukemia","volume":"41","author":"Rafeeinia","year":"2022","journal-title":"DNA Cell Biol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"6077","DOI":"10.1038\/s41467-022-33677-z","article-title":"DNA methylation at birth in monozygotic twins discordant for pediatric acute lymphoblastic leukemia","volume":"13","author":"Nickels","year":"2022","journal-title":"Nat. Commun."}],"container-title":["Current Issues in Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1467-3045\/47\/12\/988\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T12:17:01Z","timestamp":1764332221000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1467-3045\/47\/12\/988"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":46,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["cimb47120988"],"URL":"https:\/\/doi.org\/10.3390\/cimb47120988","relation":{},"ISSN":["1467-3045"],"issn-type":[{"value":"1467-3045","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,26]]}}}